Macrogenics (MGNX) Provides Vobramitamab Duocarmazine Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall St set for mixed open ahead of SK Hynix listing; Middle East in focus
- Oil heads for weekly gains as Middle East supply risks persist
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
BTIG Downgrades MacroGenics (MGNX) to Neutral
July 31, 2024 4:18 PM EDTBTIG analyst Kaveri Pohlman downgraded MacroGenics (NASDAQ: MGNX) from Buy to Neutral.
The analyst comments "MacroGenics has discontinued the Tamarack study, evaluating vobra duo for mCRPC, after a review of its risk/benefit profile. This decision follows the study's IDMC recommendation to discontinue treatment for the remaining study participants who were eligible to receive additional doses. For reference, the majority... More
